Table 1 Patient baseline characteristics
|  | Overall n = 80 | No AF recurrence n = 59 | AF recurrence n = 21 | p-value |
|---|---|---|---|---|
Demographics | ||||
 Age, mean ± SD | 58.6 ± 9.4 | 58.5 ± 11.5 | 58.6 ± 8.9 | 0.99 |
 Male | 60 (75) | 42 (71.2) | 18 (85.7) | 0.2 |
 Caucasian | 76 (95) | 54 (91.5) | 21 (100) | 0.64 |
 Prior DC cardioversion | 29 (36.3) | 23 (39) | 6 (28.6) | 0.2 |
Comorbidities | ||||
 Current/former smoker | 20 (25) | 16 (27.1) | 4 (19) | 0.29 |
 Coronary artery disease | 10 (12.5) | 9 (15.3) | 1 (4.8) | 0.16 |
 Peripheral arterial disease | 1 (1.25) | 0 | 1 (4.8) | 0.12 |
 Heart failure | 8 (10) | 7 (11.9) | 1 (4.8) | 0.28 |
 Hypertension | 38 (47.5) | 27 (45.8) | 11 (52.4) | 0.92 |
 Obstructive sleep apnea | 18 (22.5) | 11 (18.6) | 7 (33.3) | 0.33 |
 Diabetes mellitus | 3 (3.8) | 3 (5.1) | 0 | 0.27 |
 Cerebrovascular disease | 1 (1.25) | 1 (1.7) | 0 | 0.53 |
CHA2DS2-VASc score | ||||
 0 | 22 (27.5) | 16 (27.1) | 6 (28.6) | 0.79 |
 1 | 32 (40) | 21 (35.6) | 11 (52.4) | 0.45 |
 2 | 16 (20) | 13 (22) | 3 (14.3) | 0.30 |
  ≥ 3 | 10 (12.5) | 7 (11.9) | 3 (14.3) | 0.61 |
Medications | ||||
 Aspirin | 17 (21.3) | 11 (18.6) | 6 (28.6) | 0.57 |
 Statin | 29 (36.3) | 1 (1.7) | 2 (9.5) | 0.15 |
 Warfarin | 9 (11.3) | 7 (11.9) | 2 (9.5) | 0.62 |
 Apixaban | 12(15) | 9 (15.3) | 3 (14.3) | 0.73 |
 Rivaroxaban | 35(43.8) | 23 (39.0) | 12 (57.1) | 0.43 |
 Dabigatran | 4 (5) | 3 (5.1) | 1 (4.8) | 0.85 |
 Beta Blocker | 55 (68.8) | 40 (67.8) | 15 (71.4) | 0.52 |
 Calcium channel blocker | 22 (27.5) | 18 (30.5) | 4 (19) | 0.18 |
 Anti-Arrhythmic Therapy | 45 (56.3) | 32 (54.2) | 13 (61.9) | 0.33 |
 Flecanaide | 17 (21.3) | 10 (16.9) | 7 (33.3) | 0.25 |
 Propafenone | 4 (5) | 3 (5.1) | 1 (4.8) | 0.85 |
 Sotalol | 4 (5) | 1 (1.7) | 3 (14.3) | 0.04 |
 Amiodarone | 4 (5) | 4 (6.8) | 0 | 0.20 |
 Dronderone | 14 (17.5) | 11 (18.6) | 3 (14.3) | 0.48 |
 ACE/ARB | 22 (27.5) | 19 (32.2) | 3 (14.3) | 0.06 |
 Levothyroxine | 7 (8.8) | 4 (6.8) | 3 (14.3) | 0.42 |
 Diuretic | 14 (17.5) | 11 (18.6) | 3 (14.3) | 0.48 |